CagriSema is composed of the GLP-1 RA semaglutide and the long-acting insulin analog cagrilintide, and can be administered subcutaneously once a week.117 Beinaglutide Beinaglutide was the first original drug approved for the treatment of obesity in China and the third GLP-1 class reduction drug approved worldwide, and it represents a new treatment option for overweight and obese patients.67,118,119 Beinaglutide, a recombinant human GLP-1 (rhGLP-1) polypeptide, exhibits a remarkable resemblance to human GLP-1(7-36), with nearly 100% homology.120 This innovative compound demonstrates dose-dependent efficacy in regulating glycemic control, suppressing appetite, delaying gastric emptying, and facilitating weight reduction.121 Consequently, beinaglutide holds significant promise for advancing research in the areas of overweight/obesity and nonalcoholic steatohepatitis (NASH).67,122 Beinaglutide is a natural human GLP-1(7-36)-NH2 expressed in Escherichia coli
:max_bytes(150000):strip_icc()/VWH-GettyImages-2190414326-0d878e64bbf84b179058fbdc220cf21e.jpg)
The new prices will take effect starting January 1, 2027
Since Semaglutide can cause gastrointestinal side effects, which can lead to inflammation, it's important to monitor CRP levels
Semaglutide is the active ingredient in FDA-approved Ozempic and Wegovy, registered trademarks of Novo Nordisk